# reload+after+2024-01-23 13:45:42.357539
address1§Three International Towers
address2§Level 24 300 Barangaroo Avenue
city§Sydney
state§NSW
zip§2000
country§Australia
website§https://www.kaziatherapeutics.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma. It is also developing EVT801, a small molecule targeted therapeutic vascular endothelial growth factor receptor 3 inhibitor. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.
companyOfficers§[{'maxAge': 1, 'name': 'Dr. John E. Friend II, M.D.', 'age': 53, 'title': 'CEO, MD &  Interim Chairman', 'yearBorn': 1970, 'fiscalYear': 2023, 'totalPay': 741931, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Karen R. Krumeich', 'age': 69, 'title': 'Chief Financial Officer', 'yearBorn': 1954, 'fiscalYear': 2023, 'totalPay': 508183, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Anna  Sandham', 'title': 'Company Secretary', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1703980800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§2.246
priceToSalesTrailing12Months§19004.03
currency§USD
dateShortInterest§1702598400
exchange§NCM
quoteType§EQUITY
shortName§Kazia Therapeutics Limited
longName§Kazia Therapeutics Limited
firstTradeDateEpochUtc§915633000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§1898cad7-893e-3eb8-a2ff-3751c401090e
gmtOffSetMilliseconds§-18000000
targetHighPrice§2.0
targetLowPrice§2.0
targetMeanPrice§2.0
targetMedianPrice§2.0
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§1
quickRatio§0.707
grossMargins§1.0
ebitdaMargins§0.0
trailingPegRatio§None
